晚期胰腺神经内分泌癌中对anlotinib的持续反应:一个病例报告

Yan Zhang1, Yanchun Wang1, Jingjing Wu2

  • 1Department of Oncology, The 900th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Fuzong Clinical College of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China.

Oncology letters
|February 22, 2024
PubMed
概括

胰腺神经内分泌癌 (pNEC) 是罕见的. 一名患有转移性PNEC的患者在60个月以上的时间内存活下来,接受了以托波西德-西斯普拉丁化疗,随后接受了anlotinib,这表明了持续的反应.